FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2949663257> ?p ?o ?g. }

• W2949663257 endingPage "239" @default.
• W2949663257 startingPage "238" @default.
• W2949663257 abstract "Background: Lenalidomide (Len) plays an essential role in the treatment of multiple myeloma (MM). Len binds to cereblon (CRBN) and alters the substrate specificity of the CRL4CRBN E3 ubiquitin ligase. This alteration results in ubiquitination and degradation of many proteins, such as the transcription factors IKZF1, IKZF3, and nuclear transport protein KPNA2. Although several studies have investigated the expression levels of CRBN and its substrates in primary MM samples, the association between their expression levels and treatment outcomes has not been elucidated. Aims: In this study, we investigated the association between the expression levels of CRBN pathway genes and the efficacy of Len plus dexamethasone (Ld) therapy. Furthermore, the mutation status of CRBN pathway genes and the methylation status of the CRBN promoter sequence were explored in a fraction of patients both pre- and post-Ld therapy. Methods: [Gene expression] A total of 47 bone marrow (BM) specimens from relapsed MM patients were collected just prior to Ld therapy in our hospital. Among them, 25 paired BM samples were obtained both pre- and post-Ld therapy, and 22 samples were derived from patients with refractory disease to Ld. After purifying the primary MM cells from the BM specimens, mRNA levels of CRBN, IKZF1, IKZF3, CUL4A, and KPNA2 were quantified using real-time RT-PCR. The relationship between their expression levels and clinical outcomes, including best response, progression-free survival (PFS), and overall survival (OS) was analyzed. Alterations in the expression levels of these genes were also compared between pre- and post-Ld samples. [Mutation] In 22 paired samples of BM-derived genomic DNA, targeted amplicon sequencing was performed on a MiSeq (Illumina) sequencer to detect mutations in the complete coding exons of 5 genes: CRBN, IKZF1, IKZF3, CUL4A, and TP53. The average depth of sequencing coverage was 903 × . [Methylation] In 22 post-Ld samples of BM-derived genomic DNA, methylation screening of the CRBN promoter was performed by methylation-specific PCR. Results: CRBN pathway gene expression levels were not significantly associated with best response, PFS, or OS. However, the ratio of IKZF1/CRBN expression was significantly lower in poor Ld responders (SD + PD, n = 15) than in good responders (CR + VGPR + PR, n = 32) (P = 0.01). Conversely, patients with a higher ratio of KPNA2/CRBN had significantly shorter PFS and OS times than those with a lower ratio (Fig A, P = 0.01). The ratio of IKZF1/CRBN tended to be negatively correlated with the ratio of KPNA2/CRBN (Fig B, Spearman's rank correlation coefficient = −0.2311; p = 0.1223. Pearson correlation coefficient = −0.2986; p = 0.0438). There was no association between the ratios of IKZF3/CRBN and CUL4A/CRBN with the efficacy of Ld therapy. In the 22 paired samples, no mutations were observed in CRBN, IKZF1, or CUL4A, whereas somatic mutations were identified post-Ld in TP53 and IKZF3 in 2 samples and 1 sample, respectively. None of the samples showed hypermethylation of the CRBN promoter.Summary/Conclusion: In the current study, we demonstrated that a lower ratio of IKZF1/CRBN and a higher ratio of KPNA2/CRBN predicted poor outcomes of Ld therapy. Notably, a negative correlation was observed between the ratio of IKZF1/CRBN and that of KPNA2/CRBN. In clinical sample analysis, neither CRBN pathway gene mutations nor hypermethylation of the CRBN promoter was associated with lower expression levels of the CRBN gene. Thus, these results might provide us with a better understanding of the sensitivity of MM to Len treatment." @default.
• W2949663257 created "2019-06-27" @default.
• W2949663257 creator A5017360616 @default.
• W2949663257 creator A5018501206 @default.
• W2949663257 creator A5018640475 @default.
• W2949663257 creator A5028825213 @default.
• W2949663257 creator A5037722944 @default.
• W2949663257 creator A5044499778 @default.
• W2949663257 creator A5048020501 @default.
• W2949663257 creator A5056315538 @default.
• W2949663257 creator A5066823150 @default.
• W2949663257 creator A5073391500 @default.
• W2949663257 creator A5078852881 @default.
• W2949663257 creator A5084881000 @default.
• W2949663257 creator A5088750540 @default.
• W2949663257 date "2019-06-01" @default.
• W2949663257 modified "2023-09-26" @default.
• W2949663257 title "PF572 ANALYSES OF EXPRESSION LEVELS, MUTATIONS, AND METHYLATION STATUS OF CRBN-RELATED GENES PRE- AND POST-LENALIDOMIDE TREATMENT IN MULTIPLE MYELOMA" @default.
• W2949663257 doi "https://doi.org/10.1097/01.hs9.0000560576.26057.ec" @default.
• W2949663257 hasPublicationYear "2019" @default.
• W2949663257 type Work @default.
• W2949663257 sameAs 2949663257 @default.
• W2949663257 citedByCount "0" @default.
• W2949663257 crossrefType "journal-article" @default.
• W2949663257 hasAuthorship W2949663257A5017360616 @default.
• W2949663257 hasAuthorship W2949663257A5018501206 @default.
• W2949663257 hasAuthorship W2949663257A5018640475 @default.
• W2949663257 hasAuthorship W2949663257A5028825213 @default.
• W2949663257 hasAuthorship W2949663257A5037722944 @default.
• W2949663257 hasAuthorship W2949663257A5044499778 @default.
• W2949663257 hasAuthorship W2949663257A5048020501 @default.
• W2949663257 hasAuthorship W2949663257A5056315538 @default.
• W2949663257 hasAuthorship W2949663257A5066823150 @default.
• W2949663257 hasAuthorship W2949663257A5073391500 @default.
• W2949663257 hasAuthorship W2949663257A5078852881 @default.
• W2949663257 hasAuthorship W2949663257A5084881000 @default.
• W2949663257 hasAuthorship W2949663257A5088750540 @default.
• W2949663257 hasBestOaLocation W29496632571 @default.
• W2949663257 hasConcept C104317684 @default.
• W2949663257 hasConcept C134459356 @default.
• W2949663257 hasConcept C153911025 @default.
• W2949663257 hasConcept C203014093 @default.
• W2949663257 hasConcept C25602115 @default.
• W2949663257 hasConcept C2776063141 @default.
• W2949663257 hasConcept C2776364478 @default.
• W2949663257 hasConcept C2778540781 @default.
• W2949663257 hasConcept C502942594 @default.
• W2949663257 hasConcept C54355233 @default.
• W2949663257 hasConcept C71924100 @default.
• W2949663257 hasConcept C86803240 @default.
• W2949663257 hasConceptScore W2949663257C104317684 @default.
• W2949663257 hasConceptScore W2949663257C134459356 @default.
• W2949663257 hasConceptScore W2949663257C153911025 @default.
• W2949663257 hasConceptScore W2949663257C203014093 @default.
• W2949663257 hasConceptScore W2949663257C25602115 @default.
• W2949663257 hasConceptScore W2949663257C2776063141 @default.
• W2949663257 hasConceptScore W2949663257C2776364478 @default.
• W2949663257 hasConceptScore W2949663257C2778540781 @default.
• W2949663257 hasConceptScore W2949663257C502942594 @default.
• W2949663257 hasConceptScore W2949663257C54355233 @default.
• W2949663257 hasConceptScore W2949663257C71924100 @default.
• W2949663257 hasConceptScore W2949663257C86803240 @default.
• W2949663257 hasIssue "S1" @default.
• W2949663257 hasLocation W29496632571 @default.
• W2949663257 hasLocation W29496632572 @default.
• W2949663257 hasOpenAccess W2949663257 @default.
• W2949663257 hasPrimaryLocation W29496632571 @default.
• W2949663257 hasRelatedWork W1527383154 @default.
• W2949663257 hasRelatedWork W2021192126 @default.
• W2949663257 hasRelatedWork W2163060468 @default.
• W2949663257 hasRelatedWork W2587876253 @default.
• W2949663257 hasRelatedWork W2885735594 @default.
• W2949663257 hasRelatedWork W2886328430 @default.
• W2949663257 hasRelatedWork W2888011193 @default.
• W2949663257 hasRelatedWork W2917115789 @default.
• W2949663257 hasRelatedWork W3010457103 @default.
• W2949663257 hasRelatedWork W3012478396 @default.
• W2949663257 hasVolume "3" @default.
• W2949663257 isParatext "false" @default.
• W2949663257 isRetracted "false" @default.
• W2949663257 magId "2949663257" @default.
• W2949663257 workType "article" @default.